Three Springs Technology reaches commercial milestone with Resonance Health | December 2020
Three Springs Technology is pleased to announce it has entered into a commercial agreement with Resonance Health (ASX: RHT), our long valued partner in the development of AI based solutions in quantitative medical imaging. The agreement enables Three Springs Technology to market Resonance’s existing and future products and services to a range of potential clients around the world.
Products and services include but are not limited to:
| FerriSmart: A FDA, TGA and CE Mark cleared AI solution to automatically detect Liver Iron Concentration from MRI scans: https://ferriscan.com/ferrismart/ HepaFat-AI: An FDA cleared AI solution to automatically detect Liver Fat Concentration from MRI scans: https://www.hepafat.com ALERT-PE: Currently in the R&D phase, ALERT-PE is an AI based tool for the detection of suspected Pulmonary Embolism (PE) from CT scans: https://www.resonancehealth.com/news/latest-news/218-r-d-update-new-pulmonary-embolism-ai-solution-developed.html |
In addition to these AI solutions, the agreement also covers:
| Cardiac T2*: A FDA, TGA and CE Mark cleared MRI-based method for assessing heart iron loading: https://www.resonancehealth.com/products/cardiac-t2-with-ferriscan.html Bone Marrow R2-MRI: An MRI-based solution for assessing iron levels in the bone marrow: https://www.resonancehealth.com/products/bone-marrow-r2-mri.html Clinical Trial Services: Comprehensive clinical trial services for pharmaceutical companies using imaging endpoints in their Phase II, III, and IV clinical trials. |
Please contact us if you wish to find out more: info@threespringscapital.com or speak directly to James Telders, Director at Three Springs Technology: +61 (0) 429 190 655
